Superbugs Win Another Round as Big Pharma Leaves Antibiotics
Novartis AG is the latest drug giant to end antibacterial and antiviral research, joining the likes of AstraZeneca Plc, Sanofi, Allergan Plc and Medicines Co. GlaxoSmithKline Plc has put some antibiotics assets under review. Sales of new antibiotics are too low for big pharma to recoup its investments, and public measures to encourage more activity aren’t moving the needle. “We’re at a point now where resistance is moving a lot faster than our ability to provide new antibiotics.